Teva Pharmaceutical Industries (NYSE:TEVA) Announces Earnings Results, Beats Expectations By $0.01 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) posted its quarterly earnings data on Wednesday. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01, Zacks reports. Teva Pharmaceutical Industries had a positive return on equity of 40.20% and a negative net margin of 9.91%. Teva Pharmaceutical Industries updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Trading Up 1.9 %

TEVA traded up $0.34 on Friday, hitting $18.18. The company had a trading volume of 4,189,891 shares, compared to its average volume of 12,351,197. The company has a market cap of $20.60 billion, a PE ratio of -12.55, a PEG ratio of 0.97 and a beta of 0.73. The business’s fifty day simple moving average is $19.97 and its 200 day simple moving average is $18.48. Teva Pharmaceutical Industries has a 12-month low of $11.62 and a 12-month high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, Piper Sandler increased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.